Want to see VXRT full AI Analyst Report?
VXRT Stock Chart & Stats
$0.36
-$0.02(-2.57%)
At close: 4:00 PM EST
$0.36
-$0.02(-2.57%)
Day’s Range― - ―
52-Week Range$0.31 - $0.84
Previous CloseN/A
Volume1.40M
Average Volume (3M)312.09K
Market Cap
$124.65M
Enterprise Value$97.70
Total Cash (Recent Filing)$61.02M
Total Debt (Recent Filing)$7.97M
Price to Earnings (P/E)3.8
Beta1.77
Next Earnings
Jul 30, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding242,044,850
10 Day Avg. Volume319,858
30 Day Avg. Volume312,086
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.92
Price to Sales (P/S)0.34
P/FCF Ratio10.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.32
Revenue Forecast (FY)$355.90M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.
Growth PotentialVaxart's efforts to refine its norovirus program address a significant unmet need in a market with no approved vaccines, showcasing potential for growth and innovation.
Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.
Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.
Bears Say
Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.
Vaxart News
VXRT FAQ
What was Vaxart’s price range in the past 12 months?
Vaxart lowest stock price was $0.30 and its highest was $0.84 in the past 12 months.
What is Vaxart’s market cap?
Vaxart’s market cap is $124.65M.
When is Vaxart’s upcoming earnings report date?
Vaxart’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Vaxart’s earnings last quarter?
Vaxart released its earnings results on May 07, 2026. The company reported $0.02 earnings per share for the quarter, the consensus estimate of $0.02 by $0.
Is Vaxart overvalued?
According to Wall Street analysts Vaxart’s price is currently Overvalued.
Does Vaxart pay dividends?
Vaxart pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart dividends here
What is Vaxart’s EPS estimate?
Vaxart’s EPS estimate is -0.12.
How many shares outstanding does Vaxart have?
Vaxart has 242,044,850 shares outstanding.
What happened to Vaxart’s price movement after its last earnings report?
Vaxart reported an EPS of $0.02 in its last earnings report, expectations of $0.02. Following the earnings report the stock price went down -5.405%.
Which hedge fund is a major shareholder of Vaxart?
Currently, no hedge funds are holding shares in VXRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxart Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
VXRT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 10.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $6.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.56%
Trailing 12-Months
Company Description
Vaxart
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Technical Analysis
Atossa Therapeutics
―
Karyopharm Therapeutics
―
Pliant Therapeutics
―
―
Kalaris Therapeutics
―
Ownership Overview
2.66% Insiders
<0.01% Mutual Funds
0.01% Other Institutional Investors
97.32% Public Companies and
Individual Investors